Company intelligence / Profile preview

BioCrea GmbH

Radebeul, Saxony, Germany

Ownership: Private
Development stage: Other

Overview

Preclinical-stage biotech focused on CNS disorders with PDE inhibitors showing efficacy in animal models for schizophrenia, memory impairment, depression, and anxiety; developing iPSC-based screening for ALS.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Wyeth (now Pfizer)GlaxoSmithKline (GSK)Technische Universität Dresden (TU Dresden)

Beyond the preview

Go deeper on BioCrea GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCrea GmbH.

Explore the full profile